Abstract
Toll-like receptors (TLRs) are pattern-recognition receptors responsible for detecting invading pathogens. About 13 TLRs are currently known to be expressed (see Table 1). TLR2 detects lipotechoic acid and bacterial lipoproteins, TLR4 recognizes LPS, TLR5, flagellin and TLR3 detects double-stranded RNA. The unmethylated CPG DNA of bacteria and viruses is detected by TLR9. TLR7 recognizes single-stranded RNA of viruses. TLR 11 in mice recognizes profillin from Toxoplasma gondii. Binding to TLRs expressed on dendritic cells (DCs) can trigger adaptive immune responses and DCs thus serve as a bridge between innate and adaptive immunity. In HIV, it has been shown that polymorphism of the TLR9, 4, 7 and 8 plays a role in disease progression and viral load. In addition, several researchers began investigating using TLR agonists as adjuvants for HIV vaccine candidates. TLR3 has shown good results if used with vaccine proteins selectively delivered to DCs by antibodies to DEC-205/CD205, a receptor for antigen presentation. TLR7/8 and TLR9 agonists enhanced immune responses if conjugated to the vaccine protein. A triple combination of TLR2/6, -3, and -9 agonists and IL-15 synergistically up regulated immune responses to vaccine formulated as recombinant MVA viruses expressing SIVmac239 Gag, Pol, Env and Rev, Tat, Nef. These and other studies are just beginning to unravel the potential of TLRs agonists and much more and broader research is needed in order to revitalize the field of HIV vaccines.
Keywords: B cells, DCs, HIV, T cells, TLRs, polymorphism, bacterial lipoproteins, disease progression, antigen presentation, triple combination
Current Medicinal Chemistry
Title: Toll-Like Receptor Agonists as Adjuvants for HIV Vaccines
Volume: 18 Issue: 33
Author(s): L. Stevceva
Affiliation:
Keywords: B cells, DCs, HIV, T cells, TLRs, polymorphism, bacterial lipoproteins, disease progression, antigen presentation, triple combination
Abstract: Toll-like receptors (TLRs) are pattern-recognition receptors responsible for detecting invading pathogens. About 13 TLRs are currently known to be expressed (see Table 1). TLR2 detects lipotechoic acid and bacterial lipoproteins, TLR4 recognizes LPS, TLR5, flagellin and TLR3 detects double-stranded RNA. The unmethylated CPG DNA of bacteria and viruses is detected by TLR9. TLR7 recognizes single-stranded RNA of viruses. TLR 11 in mice recognizes profillin from Toxoplasma gondii. Binding to TLRs expressed on dendritic cells (DCs) can trigger adaptive immune responses and DCs thus serve as a bridge between innate and adaptive immunity. In HIV, it has been shown that polymorphism of the TLR9, 4, 7 and 8 plays a role in disease progression and viral load. In addition, several researchers began investigating using TLR agonists as adjuvants for HIV vaccine candidates. TLR3 has shown good results if used with vaccine proteins selectively delivered to DCs by antibodies to DEC-205/CD205, a receptor for antigen presentation. TLR7/8 and TLR9 agonists enhanced immune responses if conjugated to the vaccine protein. A triple combination of TLR2/6, -3, and -9 agonists and IL-15 synergistically up regulated immune responses to vaccine formulated as recombinant MVA viruses expressing SIVmac239 Gag, Pol, Env and Rev, Tat, Nef. These and other studies are just beginning to unravel the potential of TLRs agonists and much more and broader research is needed in order to revitalize the field of HIV vaccines.
Export Options
About this article
Cite this article as:
Stevceva L., Toll-Like Receptor Agonists as Adjuvants for HIV Vaccines, Current Medicinal Chemistry 2011; 18 (33) . https://dx.doi.org/10.2174/092986711797636027
DOI https://dx.doi.org/10.2174/092986711797636027 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
Current advances in inherited cardiomyopathy
Describe in detail all novel advances in multimodality imaging related to inherited cardiomyopathy diagnosis and prognosis. Shed light to deeper phenotypic characterization. Acknowledge recent advances in genetics, genomics and precision medicineread more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
To Explore the Potential Targets and Current Structure-based Design Strategies Utilizing Co-crystallized Ligand to Combat HCV
Current Drug Targets Targeting Eosinophils in Asthma
Current Molecular Medicine Immunopotentiation for Bacterial Biodefense
Current Topics in Medicinal Chemistry Bevacizumab and Angiogenesis Inhibitors in the Treatment of CNS Metastases: The Road less Travelled
Current Molecular Pharmacology Coenzyme Q10 Attenuates Cisplatin-induced Nephrotoxicity Through Counteracting Oxidative Stress and Inflammation
Clinical Cancer Drugs Editorial [Hot Topic: Alzheimers Disease: Highlights from Research on Hormones, Growth Factors and Signaling Pathways (Debomoy K. Lahiri)]
Current Alzheimer Research Protein Kinase C ζ Drives Sphingomyelin Metabolism in the Nucleus During Cell Proliferation
Current Chemical Biology Polymorphisms in TOLL-Like Receptor Genes and their Roles in Allergic Asthma and Atopy
Recent Patents on Inflammation & Allergy Drug Discovery Perioperative Levels of Adiponectin and Oxidative Stress in Patients Undergoing Laparoscopic Abdominal Surgery for Cancer
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Gene Therapy in the Transplantation of Allogeneic Organs and Stem Cells
Current Gene Therapy Bioremediation of Toxic Heavy Metals: A Patent Review
Recent Patents on Biotechnology ADAM19/Adamalysin 19 Structure, Function, and Role as a Putative Target in Tumors and Inflammatory Diseases
Current Pharmaceutical Design Distinctive Features in Spondyloarthritis Between Women and Man in Moroccan Context: Disease Beginning, Clinical Manifestations, Disease Activity and Function Scores
Current Rheumatology Reviews Non-Integrating Lentiviral Vectors
Current Gene Therapy Nano-Therapeutics for the Lung: State-of-the-Art and Future Perspectives
Current Pharmaceutical Design Overlapping the Tryptophan Catabolite (TRYCAT) and Melatoninergic Pathways in Alzheimer's Disease
Current Pharmaceutical Design RNA Interference-Based Therapeutics: New Strategies to Fight Infectious Disease
Infectious Disorders - Drug Targets The Relationship Between FoxP3 and SOCs3 Gene Expressions and Disease Activity in Rheumatoid Arthritis
Current Rheumatology Reviews Inflammasome as a New Therapeutic Target for Diabetic Complications
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Editorial (Cellular Senescence and Inflammation: Advances and Therapeutic Targets in Aging and Major Age-Related Diseases)
Current Pharmaceutical Design